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DISCLAIMER: This is a theoretical proposal done as an intellectual exercise.

Abstract
This is a theoretical proposal done as an intellectual exercise. The purpose of
this project is to practice and familiarize oneself with the process of applying for a grant
from the National Institute of Health to conduct research on human subjects. This
proposed study plans to sequence blood samples from infected individuals, exposed
and uninfected individuals, and unexposed individuals from the 2018 outbreak in the
Democratic Republic of Congo to determine the presence of polymorphisms in TNF
production as they relate to Ebolavirus infection. It is hypothesized that certain
polymorphisms in the regulation and production of TNF that cause a decreased
production thereof have a protective effect against Ebola disease. This hypothesis is
based on a synthesis of other’s published work. Completion of this study will identify key
polymorphic targets for developing interventions and allocating healthcare resources
during a potential future Ebola epidemic in the Democratic Republic of Congo. The work
proposed here will also develop experimental techniques and understanding of
infectious disease immunology and genetics that together will constitute a widelyapplicable platform for assessing risk during other disease outbreaks.
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Project Title:
Determining polymorphisms in TNF production as they relate to infection with EBOV

Project Summary/Abstract:
Ebola virus has surfaced several times since its discovery in 1976 to cause
devastating outbreaks in the continent of Africa. The most recent outbreak took place in
the Democratic Republic of Congo (DRC) from 2018-2020. This was the largest Ebola
outbreak in the DRC, and the second largest Ebola outbreak in the world. Better
methods for diagnosis and intervention are necessary to prevent future outbreaks from
becoming worse. This proposed study plans to sequence blood samples from infected
individuals, exposed and uninfected individuals, and unexposed individuals from the
2018 outbreak in the North Kivu province of the Democratic Republic of Congo to
determine the presence of polymorphisms in TNF production as they relate to
Ebolavirus infection. It is hypothesized that certain polymorphisms in the regulation and
production of TNF that cause a decreased production thereof have a protective effect
against severe Ebola disease. This hypothesis is based on a synthesis of other’s
published work. Completion of this study will identify key polymorphic targets for
developing interventions and allocating healthcare resources during a potential future
Ebola epidemic in the Democratic Republic of Congo or elsewhere. The work proposed
here will also develop experimental techniques and understanding of infectious disease
immunology and genetics that together will constitute a widely-applicable platform for
assessing risk during other disease outbreaks.
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Project Narrative:
The proposed research is relevant to public health because it will allow
physicians and healthcare workers to determine whether a patient is more or less at risk
of succumbing to Ebola before infection even occurs. This could determine when and
where interventions to stop disease course and spread should occur. This proposal is
relevant to the part of NIH’s mission that pertains to fostering fundamental creative
discoveries and innovative research strategies as a basis for ultimately protecting
health.
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Specific Aims:
This proposal’s objective is to determine the impact that polymorphisms in TNF
production have on Ebola disease progression.
Infection with Ebolavirus is characterized by an abnormal host immune response
known as a cytokine storm. A cytokine storm is when vast quantities of different
inflammatory cytokines are produced in a short period of time. One of these cytokines
is the tumor necrosis factor, or TNF. This cytokine is responsible for signaling cells to
apoptosis. Therefore, a sudden influx of TNF would result in mass cell death, leading to
organ failure and death in Ebola patients. A polymorphism preventing increased TNF
production would theoretically aid in preventing increased cell death and organ
damage in an individual. The work we propose to conduct will determine whether this
is true, as well as open new possibilities for study in TNF polymorphisms and their
relation to Ebolavirus.
Our long-term goal is to explore genetic risk factors as they relate to Ebola
disease by examining blood samples. Here, our central hypothesis is that certain
polymorphisms in the regulation and production of TNF that cause a decreased
production have a protective effect against Ebola disease. This hypothesis is based on
a synthesis of other’s published work. The rationale is that completion will identify key
polymorphic targets for developing interventions and allocating healthcare resources
during a potential future Ebola epidemic in the Democratic Republic of Congo. The work
we propose here will also develop experimental techniques and understanding of
infectious disease immunology and genetics that together will constitute a widelyapplicable platform for assessing risk during other disease outbreaks.
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We will test our central hypothesis and attain our objective via the following
specific aims:
1: To determine whether there is a polymorphism in TNF production. For this, we
will use blood samples from uninfected and unexposed individuals and infect them with
either activated or inactivated Ebola virus. We will also use ELISA assays to examine
the levels of TNF produced upon infection. A DNA sequencer will be used to determine
whether samples that produced less TNF contained a polymorphism that led to this
diminished production. Working hypothesis: Individuals who have lower TNF production
upon infection with Ebola have a polymorphism in the TNF-alpha gene.
2: To determine the role of TNF in Ebola disease progression. For this, we will use
blood serums of recently infected individuals, as well as serums throughout their
disease progression. ELISA assays will be used to examine the levels of TNF, and
when they are varying. We will simultaneously measure the levels of cytokines related
to TNF. This aim is not completely dependent on the first aim, as there may or may not
be a genetic difference between samples. Working hypothesis: Mortality will be
dependent on high levels of TNF, with low levels being protective against death from
Ebola.
The expected outcome of this work is a comprehensive understanding of how
genetic capabilities of TNF production may be a risk factor for succumbing to Ebola
disease. The results will have an important positive impact because they lay the
groundwork to develop further studies on understanding the role of TNF in Ebola.
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Research Strategy:
A) Significance:
Ebola virus was discovered in the 1970s in what is now the Democratic Republic of
Congo (Feldmann et al 2011). The virus causes a hemorrhagic fever that currently has
a 60% mortality rate (Feldmann et al 2011). Transmission between humans occurs
through contact with bodily fluids including saliva and blood.
Research into how exactly the virus works in the body is limited, since outbreaks
usually occur in remote areas where data collection is difficult. However, it is known that
Ebola infection is characterized by a cytokine storm immune response in the host
(Feldmann et al 2011). A cytokine storm is when different inflammatory cytokines are
produced at a significantly higher rate than what is considered normal.
Infection with Ebolavirus triggers the expression of several inflammatory cytokines
including interferons, interleukins 2, 6, 8, and 10, interferon-inducible protein 10,
monocyte chemoattractant protein 1, TNFα, and reactive oxygen and nitrogen species
(Wauquier et al, 2010). Although monocytes or macrophages seem to produce many of
these cytokines, as shown in vitro, other cell types could produce inflammatory
cytokines in the intact animal or person. Overall, virus-induced expression of these
cytokines seems to result in an immunological imbalance that partly contributes to the
progression of disease. Proinflammatory responses recorded in fatal cases of Ebola
hemorrhagic fever are dysregulated, whereas early and well-regulated inflammatory
responses have been associated with recovery (Wauquier et al, 2010).
Inhibition of the type I interferon response is a key feature of filovirus pathogenesis.
The Ebola virus viral protein (VP) 35 functions as a type I interferon antagonist, by
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blocking activation of interferon regulatory factor 3 and possibly by preventing
transcription of interferon β (Wauquier et al, 2010). Additionally, other studies suggest
that expression of VP24 of the Ebola virus interferes with type I interferon
signaling; mutations in VP24 have been linked to adaptation of Zaire Ebola virus to
produce lethal disease in mice and Guinea pigs (Feldmann et al, 1999).
Results from several studies show an important role for reactive oxygen and
nitrogen species in pathogenesis of Ebola hemorrhagic fever (Hensley et al, 2002).
Increased concentrations of nitric oxide in blood were reported in non-human primates
experimentally infected with Zaire Ebola virus and were noted in patients infected with
Zaire Ebola virus and Sudan Ebola virus. Increased blood concentrations of nitric oxide
in patients were associated with mortality. Abnormal production of nitric oxide has been
associated with several pathological disorders including apoptosis of bystander
lymphocytes, tissue damage, and loss of vascular integrity, which might contribute to
virus-induced shock. Nitric oxide is an important mediator of hypotension, and
hypotension is a prominent finding in most of the viral hemorrhagic fevers including
those caused by Ebola virus (Hensley et al, 2002).
Lymphocytes are depleted by apoptosis even though they are not susceptible to
Ebola infection, and the apoptosis is likely to be due to impairment of dendritic cells,
proapoptotic factors from activated monocytes/macrophages and direct effect of viral
glycoproteins (Morikawa et al, 2007).
In summation, an impaired and ineffective host innate immune response leads to
high concentrations of virus and proinflammatory mediators in the late stages of
disease, which is important in the pathogenesis of hemorrhage and shock. The
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prevailing data suggest that infection and activation of antigen-presenting cells is
fundamental to the development of Ebola hemorrhagic fever. The release of
proinflammatory cytokines, chemokines, and other mediators from antigen presenting
cells, and perhaps other cells, causes impairment of the vascular and coagulation
systems leading to multiorgan failure and a syndrome that in some ways resembles
septic shock. The goal of this proposed study is to determine whether the genetic
variation in cytokines released during the cytokine storm (TNF specifically) determines
the outcome of disease.
B) Innovation:
The common approaches to studying disease progression of Ebolavirus is to infect
primates, mice, or other model organisms and observe the outcome. This study will
build upon what is already known by using human blood samples in two different and
novel ways. First, unexposed samples will be infected with Ebolavirus to determine the
difference in TNF production. Second, samples of infected individuals will be used to
observe TNF and cytokine production in relation to disease progression. Our approach
will allow for clear results that will either support or deny our hypotheses.
C) Approach:
Research Personnel:
This will be a joint effort between the Ebola Treatment Center at the Beni
General Hospital in Beni, DRC, and the National Institute of Allergy and Infectious
Disease Integrated Research Facility in Frederick, Maryland and both their staff.
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Specific Aim 1: To determine whether there is a polymorphism in TNF production.
Introduction:
The objective of this aim is to determine what polymorphisms occur in the TNFalpha gene and how those affect TNF production upon infection with Ebolavirus. At this
point, there is no specific polymorphisms in mind, any and all will be sequenced and
vetted equally against the regular TNF-alpha gene. The working hypothesis of this aim
is that a polymorphism in the TNF-alpha gene is seen in samples that produce lower
levels of TNF. Our approach to testing this working hypothesis will be to use ELISA
assays to measure TNF levels and to use DNA sequencers to sequence the TNF-alpha
genes.
Justification and Feasibility:
Several TNF-alpha polymorphisms associated with TNF production have been
identified. There have studies where lowered TNF production due to a polymorphism
have been beneficial, such as with tuberculosis where reduced production of TNF due
to polymorphisms leads to the inability of the tuberculosis to maintain its granuloma,
garnering protection (Correa et al, 2005). Other studies have observed that lowered
TNF promotes infection, such as with chronic hepatitis B, where low TNF production is
linked to defective viral clearance (Zum et al, 1998). Most studies, however, describe
TNF’s relationship with autoimmune disease rather than infectious diseases. Since
there is a lot unknown about TNF polymorphisms reacting to foreign infections, this
proposed study will only add to the limited resources in the field.
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Research Design:
This aim will be completed in three parts. The first part will be accomplished by
obtaining, storing, and infecting blood samples from individuals who were uninfected
and unexposed to Ebolavirus in the areas surrounding Beni. These surrounding areas
will be from the Tshopo and Maniema provinces, as they were less affected by the
outbreak, and are more likely to have unexposed individuals (Mbala-Kingebeni et al,
2021). The second part will be accomplished by using commercially available ELISA
kits according to manufacturer’s directions to measure the levels of TNF produced upon
infection. The assays will be performed 5 days post infection, as this is considered late
stage disease and will have been sufficient time to allow for TNF production (Hensley et
al, 2002). The third part will be accomplished by using a DNA sequencer to determine
whether samples that produced less TNF contained a polymorphism that led to this
diminished production. All polymorphisms found will be considered and ranked against
samples containing regular TNF during analysis.
Expected Outcomes:
The overall outcome of this aim will be comprehensive knowledge of structure
and makeup of TNF and its respective polymorphisms upon Ebola infection. This
knowledge will be used to identity individuals with key polymorphisms that lower TNF
production.
Potential Pitfalls and Possible Alternatives:
It will be difficult to ensure samples from unexposed individuals in surrounding
areas of Beni are actually unexposed. If we are unable to obtain enough samples to
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conduct a thorough analysis, we will use samples from individuals in the US who have
not traveled to the DRC, so as to ensure complete unexposure.
Specific Aim 2: To determine the role of TNF in Ebola disease progression.
Introduction:
The objective of this aim is to determine how production of TNF in an Ebolainfected individual affects disease progression. The working hypothesis of this aim is
that low levels of TNF production will be protected against death from Ebola.
Conversely, our hypothesis also includes that high levels of TNF will be associated with
greater mortality from Ebola disease. Our approach to testing this working hypothesis
will be to use ELISA assays to examine levels of TNF at different intervals upon
infection.
Justification and Feasibility:
There is previous literature indicating that infection with Ebolavirus promotes
production of TNF. Hensley et al conducted a study in 2002 where they collected sera
and plasma from nonhuman primates and assayed the samples to determine levels
production of several different cytokines (Hensley et al, 2002). Samples were taken preexposure (before they were purposefully infected), at the early stage of disease (2-3
days post infection), late stage of disease (5-6 days post infection), and the terminal
stage of disease (6-7 days post infection). There were no detectable cytokines observed
in the early disease stages. By day 5, there was increased IFN and TNF-alpha in 75%
of the samples. Infection was lethal to all nonhuman primates infected. This indicates
that there is an initial release of TNF, followed by a drop in production and then a
gradual increase.
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Fig. 1. Analysis of cytokine accumulation in EBOV-infected nonhuman primates. EBOV represents
infectious Ebolavirus, EBOV-g represents inactivated ebolavirus. (Hensley et al, 2002)

Research Design:
This aim will involve several extractions of blood samples from recently infected
individuals. First, individuals who were recently infected must be identified in the Beni
General Hospital. Determining how recent the infection was will be the responsibility of
the Hospital staff to inform us when diagnosis occurred. The earlier the diagnosis, the
more accurate our results will be. Once infected individuals are identified, blood
samples will be taken at predetermined intervals throughout their disease progression.
These intervals are at diagnosis, at the early stage of disease (2-3 days post infection),
late stage of disease (5-6 days post infection), and the terminal stage of disease (6-7
days post infection). Each sample will be stored properly until the ELISA assay to
ensure that they were not corrupted or damaged, affecting our results. Once samples
are determined to be intact, they are to be assayed by using commercially available
ELISA kits according to manufacturer’s directions to measure TNF levels. The different
levels will be observed over time, allowing us to determine any trends in TNF production
upon Ebolavirus infection.
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Expected Outcomes:
The overall outcome of this aim will be an understanding of the role of TNF in
Ebola disease progression. This knowledge will be used to determine which individuals
have a higher risk of mortality upon infection.
Potential Pitfalls and Possible Alternatives:
Our working hypothesis is that the higher levels of TNF produced will increase
the chance of mortality in an individual. This requires that we perform ELISA assays at
predetermined checkpoints before and after infection with Ebolavirus. Missing a
checkpoint or incorrectly determining that checkpoint will result in inconsistent data. It
can be difficult to determine exact checkpoints since it will be difficult to determine when
exactly individuals were infected. To ameliorate this potential mishap, we will ensure
that there are multiple reminders put in place to remind the staff of when to take
measurements, as well as alerting staff at the Beni Treatment Center to record exactly
when infection was diagnosed.
Use of Human Subjects:
This study involves the analysis of human blood samples to be collected at the
Beni Ebola Treatment Center and surrounding areas. Although usually painless, there is
a small risk of a cut to the skin from the needle used for extraction, or lightheadedness
from extracting too much blood. The Beni General Hospital (where the Ebola Treatment
Center is found) has been collecting blood samples since its inception, and therefore
the staff is well trained in how to obtain blood samples with minimal to no injury to the
individual.
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